Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Hong Kong Connect Flows: Tencent, Ganfeng Lithium, Meituan, Kuaishou, Wuxi Biologics

Hong Kong Connect Flows: Tencent, China Mobile, Meituan and Kuaishou

Hong Kong Connect Flows: Meituan, Kuaishou

Hong Kong Connect Flows: 11 Weeks of Inflows

Hong Kong Connect Flows: Tencent, Geely, Meituan, Wuxi Biologics

Hong Kong Connect Flows: Tencent, Li Auto, CCB, Pharmaron

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding as of July  29th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Tencent, Wuxi Biologics, and China Mobile.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding as of July  29th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Tencent, Wuxi Biologics, and China Mobile.


China Overseas Land & Investment (688 HK)

Hong Kong Connect Flows: Tencent, Wuxi Biologics, China Mobile